Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants | Novartis | Completed | Meningococcal ACWY Conjugate Vaccine | 3b | V59P23 | King Fahad Medical City (Riyadh) |
| An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. | Novartis | Completed | Everolimus | 3b | CRAD001K24133 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" | Novartis | Completed | TKI258 / Sorafenib | 3 | CTKI258A2302 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd) | Novartis | Completed | Nilotinib | 3b | CAMN107E2401 | King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital and Oncology Center (Jeddah) |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) | AstraZeneca | Ongoing | Tezepelumab | 3 | D5180C00018 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| Comparison of the Efficacy and Safety for different regimen of Venous Thromboembolism pharmacoprophylaxis among Severely Burn Patients: A Multicenter, Randomized Controlled Trial | KAIMRC | Ongoing | HEPARIN SODIUM, ENOXAPARIN SODIUM | 4 | RC18/400/R | King Abdulaziz Medical City NG (Riyadh) |
| Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma | SANOFI | Ongoing | DUPILUMAB | 4 | LPS15834 | King Fahad Medical City (Riyadh) |
| Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis | Eli Lilly | Ongoing | Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care | 4 | 1F-MC-B007 | Hira Hospital (Makkah) |
| Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) | Abbvie | Ongoing | Drug choice as per treating physician which is not limited per the protocol | 4 | H19-940 | Hira Hospital (Makkah), Security Force Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Sanofi | Ongoing | DUPILUMAB | 4 | OBS15990 | King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.